-
Study aim
-
Evaluation of the effect of Remdesivir in patients with acute or chronic renal failure with Covid 19
-
Design
-
A clinical trial with a control group, parallel groups, one-way blind, randomized, on 100 patients, use the block method (with unequal quadruple sizes) for random allocation.
-
Settings and conduct
-
Patients referred to Shohada-e-Tajrish Hospital who were eligible for the study received 200 mg of injectable remdesivir on the first day and then 100 mg every other day.
This drug is diluted in 200 cc of normal saline for injection.
The control group also received 200 cc of normal saline as a placebo.
hepatic and renal complications and function are evaluated and the usefulness of this treatment and recovery is monitored.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: Acute or chronic renal failure with a definitive diagnosis of Covid 19 admitted to the ward ,in the age over 18 years and lung involvement .
Exclusion criteria: previous history of COVID-19 and receiving remdesivir, history of lung disease, liver ,Patients admitted in ICU from the beginning, prohibition of remdesivir (except low GFR),Underlying diseases other than renal dysfunction (such as heart failure, active cancer,Advanced diabetes, previous stroke),Immunosuppressive use except in the field of kidney transplantation.
-
Intervention groups
-
Patients in the intervention group receive first 200 mg of remdesivir on the first day and then one day between 100 mg Up to 5 doses until the patient recovers or develops complications from remdesivir.The control group receives standard treatment without remdesivir.
-
Main outcome variables
-
Duration of hospitalization,Result of hospitalization (death or discharge),Red blood cell count, Platelet count ,White blood cell count, Mean platelet volume,ESR,CRP,AST,ALT,INR,Bilirubin,ALK,Cr,O2 Sat,Lymphocyte cell count,neutrophil count